Clinical Trial

The Impact of Qualia Gluthathione+ on Blood Glutathione Levels

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2025 (before its estimated December 22, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-24.
Trial Details
NCT Number NCT07221955
Lead Sponsor Qualia Life Sciences
Conditions Effects of Qualia Glutathione+ on Blood Glutathione Levels, Glutathione
Enrollment 54 participants
Start Date 2025-12-02
Primary Completion 2025-12-22 (estimated)
Study Completion 2026-01-25 (estimated)
Updated on ClinicalTrials.gov 2025-11-14